Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK 1557484A H5N1 Vaccine in Adults
NCT01045564Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Jan 2011
- Primary completion
- Feb 2013
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised trial of influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) in Influenza A H5N1 (H5N1) (5 arms), sponsored by GSK. Primary endpoint: Booster humoral immune response in terms of Hemagglutination Inhibition (HI) antibodies. Planned start Jan 2011; status: withdrawn.
02
Drugs
influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia)
03
Conditions
Influenza A H5N1 (H5N1)
Beyond the preview
Go deeper on NCT01045564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01045564.